EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing Neuroprotection

Sergi Verdés iD, Xavier Navarro, Assumpció Bosch

Human Gene Therapy · 2025

DOI: 10.1177/10430342251372898 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Gene Therapy, 2025. Verfasst von Sergi Verdés und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Genetic Therapy, Gene Silencing, Neuroprotection. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 180 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene therapy is emerging as a transformative approach for treating amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disease. While gene replacement has shown a groundbreaking success in spinal muscular atrophy, the complexity of ALS-due to frequent gain-of-function mutations and a heterogeneous etiology-presents significant challenges. Importantly, approximately 90% of ALS cases are sporadic, with unknown genetic mutation, further complicating patient stratification and therapeutic targeting. As a result, gene therapy strategies must often address multiple pathological mechanisms simultaneously. So far, current gene therapy strategies aim to either suppress toxic gene expression or promote neuroprotection, predominantly via viral-mediated delivery systems. This review will provide an overview of emerging preclinical and clinical gene therapy approaches for ALS, focusing on two main strategies: gene silencing and neuroprotection. Gene silencing techniques, including antisense oligonucleotides (ASOs), viral-mediated RNA interference, and gene editing, have demonstrated efficacy in reducing mutant gene expression, particularly in SOD1 and C9orf72 models, although clinical translation has so far yielded limited success. The recent Food and Drug Administration's approval of the ASO therapy Qalsody for SOD1-ALS underscores the clinical potential of these approaches. Neuroprotective strategies aim to enhance motor neuron survival through delivery of trophic factors, often targeting both central and peripheral tissues to harness retrograde transport mechanisms. We will discuss the advantages and limitations of various delivery vectors, targeting specificity, timing of intervention, and translational challenges, alongside current clinical trial data. This review aims to synthesize how these approaches may converge to address the multifaceted nature of ALS and guide the development of next-generation therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisGenetic TherapyGene SilencingNeuroprotectionHumansSuperoxide Dismutase-1AnimalsOligonucleotides, AntisenseGenetic VectorsC9orf72 ProteinGene EditingRNA Interference

Stichwörter der Autor:innen

ALSdelivery routesgene augmentationgene silencingmotor neuronneuromuscular

Substanzen

Superoxide Dismutase-1Oligonucleotides, AntisenseC9orf72 ProteinSOD1 protein, human

Autor:innen und Institutionen

  • Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Unitat Mixta UAB-VHIR, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
  • Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Sergi Verdés

Zitieren

APA

Verdés, S., Navarro, X., & Bosch, A. (2025). Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing Neuroprotection. Human Gene Therapy. https://doi.org/10.1177/10430342251372898

Vancouver

Verdés S, Navarro X, Bosch A. Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing Neuroprotection. Human Gene Therapy. 2025. doi:10.1177/10430342251372898

BibTeX
@article{Verds2025,
  author = {Verdés, Sergi and Navarro, Xavier and Bosch, Assumpció},
  title = {Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing Neuroprotection},
  journal = {Human Gene Therapy},
  year = {2025},
  doi = {10.1177/10430342251372898}
}
Kostenlos starten →